Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Pembrolizumab/Eribulin Combo Shows Promise for TNBC

December 10th 2016

The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.

IBM's Watson Achieves High Concordance in Tumor Board Test

December 10th 2016

The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

AI Therapy May Pose Cardiovascular Risk for Breast Cancer Survivors

December 10th 2016

Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.

Women With Menopausal Symptoms Less Likely to Adhere to Breast Cancer Prevention Treatment

December 10th 2016

Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.

Ribociclib Shows Consistent Benefit in Advanced Breast Cancer Subgroups

December 10th 2016

A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.

Sacituzumab Govitecan Elicits Durable Responses for Pretreated TNBC

December 10th 2016

Treatment with sacituzumab govitecan was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer.

More Evidence That Scalp Cooling Devices Work, Especially During Taxane-Based Chemotherapy

December 9th 2016

Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.

Prophylactic Regimen Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer

December 9th 2016

Prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade ≥3 diarrhea associated with neratinib to 15% compared with 39.9% observed in the ExteNET trial.

New Mechanism of Action Results Renew Interest in Eribulin

December 9th 2016

There has been renewed interest in eribulin mesylate following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti–mesenchymal mechanism of action.

Dr. Robertson on Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer

December 9th 2016

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.

Neoadjuvant Estrogen Attack Falters in High-Risk Breast Cancer Patients

December 9th 2016

An attempt to strengthen neoadjuvant treatment of patients with locally advanced HR-positive and HER2-positive breast cancer by adding estrogen deprivation therapy to a standard regimen failed to significantly improve response rates but did illustrate the extensive toxicity of the chemotherapy agents used in this setting.

Biomarker Analysis Shows Promise for Predicting Breast Cancer Response

December 9th 2016

A biomarker analysis of participants in a phase II breast cancer trial demonstrated potential for identifying tumor markers to predict susceptibility to specific therapies.

HER2-Enriched Breast Tumor Subtype Predicts Response to HER2 Dual Blockade

December 9th 2016

The HER2-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy.

No Clinical Benefit With Adjuvant Ibandronate in Postmenopausal Breast Cancer

December 9th 2016

Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.

Neoadjuvant Abemaciclib Active in HR+/HER2- Breast Cancer

December 9th 2016

A neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole induced a response rate of 54.7% in patients with HR+/HER2-negative early-stage breast cancer, according to findings from the phase II neoMONARCH trial.

Hormonal Therapy Effectively Added to Dual HER2-Blockade in Phase II PERTAIN Study

December 8th 2016

The addition of an aromatase inhibitor (AI) to pertuzumab and trastuzumab improved progression-free survival by 3.09 months, when compared with trastuzumab plus an AI.

Buparlisib Combo Modestly Effective in Pretreated HR+ Breast Cancer

December 8th 2016

Median progression-free survival was improved by 2.1 months with the addition of the pan-PI3K inhibitor buparlisib to fulvestrant for women with HR-positive/HER2-negative advanced breast cancer who received a prior aromatase inhibitor and progressed on or after an mTOR inhibitor.

Six Years of Anastrozole After Adjuvant Tamoxifen Not Better Than 3 Years

December 8th 2016

First results from the phase III DATA study show no advantage to extending anastrozole therapy from 3 years to 6 for the primary endpoint of 5-year adapted disease-free survival.

Mixed Results on Benefit of Extending Letrozole Beyond 5 Years of Prior Endocrine Therapy

December 8th 2016

Extending letrozole therapy in women with early-stage, HR-positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival, but prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.

Genomic Study Uncovers Resistance Mutations in ER+ Breast Cancer

December 8th 2016

The genomic landscape of recurrent metastatic estrogen receptor–positive breast cancer differed significantly from the mutational profile of primary disease in a study that sheds light on acquired resistance mechanisms to anticancer therapies.